Video

Dr. Dreicer on Newer Prostate Therapy Survival Benefits

Author(s):

Robert Dreicer, MD

Robert Dreicer, MD, from the Taussig Cancer Institute, Discusses How New Treatments Have Improved Survival

Robert Dreicer, MD from the Taussig Cancer Institute, explains that the survival benefits observed for abiraterone acetate (Zytiga) and sipuleucel-T (Provenge) are both in the range of 4 months. Additionally, post docetaxel the agent cabazitaxel also improves survival. Since all of these agents improve survival the questions becomes how do you use them, should you combine, and in which population.

Related Videos
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD
Vikram M. Narayan, MD
C. Ola Landgren, MD, PhD
Related Content
Philip Sutera, MD, of Johns Hopkins University School of Medicine
May 30th 2024

PSMA Response Is Associated With MFS Improvement in Oligometastatic CSPC

Neeraj Agarwal, MD
July 17th 2023

FDA Approval Insights: Talazoparib Plus Enzalutamide in HRR Gene–Mutated mCRPC

FDA
May 28th 2024

FDA Approval Sought for Use of TLX007-CDx in PSMA PET Imaging of Prostate Cancer

Andrew J. Armstrong, MD, MSc
June 15th 2023

FDA Approval Insights: Olaparib Plus Abiraterone in BRCA-Mutated mCRPC

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC
May 6th 2024

Darolutamide Use Is Routine in Both Doublets and Triplet Therapies in mHSPC

Marcelo Bigarella, MD
May 4th 2024

PSMA-PET Plus Multi-Parametric MRI Aids Detection of Clinically Significant Prostate Cancer